

## S 2609

### Facilitating Innovative Nuclear Diagnostics Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Aug 4, 2021

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Aug 4, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/2609>

## Sponsor

**Name:** Sen. Blackburn, Marsha [R-TN]

**Party:** Republican • **State:** TN • **Chamber:** Senate

## Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Aug 4, 2021
Sen. Sullivan, Dan [R-AK]	R · AK		Dec 7, 2021
Sen. Duckworth, Tammy [D-IL]	D · IL		Feb 3, 2022
Sen. Capito, Shelley Moore [R-WV]	R · WV		Apr 27, 2022
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Sep 21, 2022

## Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Aug 4, 2021

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

Bill	Relationship	Last Action
117 HR 4479	Identical bill	Jul 19, 2021: Referred to the Subcommittee on Health.

## Summary (as of Aug 4, 2021)

### Facilitating Innovative Nuclear Diagnostics Act of 2021

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of \$500 or more in 2022 and as adjusted based on a specified fee schedule factor in each year thereafter.

## **Actions Timeline**

---

- **Aug 4, 2021:** Introduced in Senate
- **Aug 4, 2021:** Read twice and referred to the Committee on Finance.